Cornelius Engelmann1, Thomas Berg1. 1. Section Hepatology, Department of Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany.
Abstract
INTRODUCTION: Acute-on-chronic liver failure (ACLF) is associated with a high susceptibility to infections leading to complications and poor prognosis. The sensitized immune system overwhelmingly responds to invading bacteria leading to organ damage. After resolution of infection or prolonged disease duration, the phagocytic system becomes irresponsive with a reduced bacterial clearance capacity promoting secondary infection. METHODS: This review focuses on the best management strategies for patients with ACLF and infections. Using the following terms, an extensive literature research on the Medline database was performed: 'acute-on-chronic liver failure', 'infection', 'ACLF', 'bacteria', 'multi-resistance'. RESULTS: Analysis of the literature confirmed that delayed diagnosis and treatment of infections in patients with ACLF results in a poor prognosis. Patients with ACLF should be considered as having a potential infection and should undergo a complete screening for sepsis. Once biochemical analysis indicates a potential infection, such as abnormal levels of C-reactive protein and procalcitonin, antibiotic treatment should be initiated immediately without microbiological culture results. For community-acquired infections third-generation cephalosporins are still the first choice, whereas in the nosocomial setting antibiotics with broader spectrum, such as piperacillin/combactam or carbapenems ± glycopeptides, are preferred. The patient should be re-assessed 48 h after treatment initiation in order to tailor the treatment. Non-response is suspicious, likely due to bacterial resistance or fungal infection, which should be considered when choosing further treatment strategies. Albumin substitution to prevent hepatorenal syndrome and to improve patients' outcome is mandatory in patients with spontaneous bacterial peritonitis. Prophylactic antibiotic therapy is suitable to prevent infections in high-risk patients. CONCLUSION: The screening for infections and its treatment is an essential part of managing patients with ACLF. In order to improve patients' prognosis, antibiotic treatment should be initiated once an infection is suspected. However, preventive strategies are already established and should be applied according to the guidelines.
INTRODUCTION: Acute-on-chronic liver failure (ACLF) is associated with a high susceptibility to infections leading to complications and poor prognosis. The sensitized immune system overwhelmingly responds to invading bacteria leading to organ damage. After resolution of infection or prolonged disease duration, the phagocytic system becomes irresponsive with a reduced bacterial clearance capacity promoting secondary infection. METHODS: This review focuses on the best management strategies for patients with ACLF and infections. Using the following terms, an extensive literature research on the Medline database was performed: 'acute-on-chronic liver failure', 'infection', 'ACLF', 'bacteria', 'multi-resistance'. RESULTS: Analysis of the literature confirmed that delayed diagnosis and treatment of infections in patients with ACLF results in a poor prognosis. Patients with ACLF should be considered as having a potential infection and should undergo a complete screening for sepsis. Once biochemical analysis indicates a potential infection, such as abnormal levels of C-reactive protein and procalcitonin, antibiotic treatment should be initiated immediately without microbiological culture results. For community-acquired infections third-generation cephalosporins are still the first choice, whereas in the nosocomial setting antibiotics with broader spectrum, such as piperacillin/combactam or carbapenems ± glycopeptides, are preferred. The patient should be re-assessed 48 h after treatment initiation in order to tailor the treatment. Non-response is suspicious, likely due to bacterial resistance or fungal infection, which should be considered when choosing further treatment strategies. Albumin substitution to prevent hepatorenal syndrome and to improve patients' outcome is mandatory in patients with spontaneous bacterial peritonitis. Prophylactic antibiotic therapy is suitable to prevent infections in high-risk patients. CONCLUSION: The screening for infections and its treatment is an essential part of managing patients with ACLF. In order to improve patients' prognosis, antibiotic treatment should be initiated once an infection is suspected. However, preventive strategies are already established and should be applied according to the guidelines.
Authors: Joan Clària; Rudolf E Stauber; Minneke J Coenraad; Richard Moreau; Rajiv Jalan; Marco Pavesi; Àlex Amorós; Esther Titos; José Alcaraz-Quiles; Karl Oettl; Manuel Morales-Ruiz; Paolo Angeli; Marco Domenicali; Carlo Alessandria; Alexander Gerbes; Julia Wendon; Frederik Nevens; Jonel Trebicka; Wim Laleman; Faouzi Saliba; Tania M Welzel; Agustin Albillos; Thierry Gustot; Daniel Benten; François Durand; Pere Ginès; Mauro Bernardi; Vicente Arroyo Journal: Hepatology Date: 2016-08-25 Impact factor: 17.425
Authors: Javier Fernández; Juan Acevedo; Miriam Castro; Orlando Garcia; Carlos Rodríguez de Lope; Daria Roca; Marco Pavesi; Elsa Sola; Leticia Moreira; Anibal Silva; Tiago Seva-Pereira; Francesco Corradi; Jose Mensa; Pere Ginès; Vicente Arroyo Journal: Hepatology Date: 2012-04-04 Impact factor: 17.425
Authors: John J Kim; Michelle M Tsukamoto; Arvind K Mathur; Yashar M Ghomri; Linda A Hou; Sarah Sheibani; Bruce A Runyon Journal: Am J Gastroenterol Date: 2014-08-05 Impact factor: 10.864
Authors: M Assem; M Elsabaawy; M Abdelrashed; S Elemam; S Khodeer; W Hamed; A Abdelaziz; G El-Azab Journal: Hepatol Int Date: 2015-12-10 Impact factor: 9.029
Authors: David U Lee; Gregory H Fan; David J Hastie; Vibhav N Prakasam; Elyse A Addonizio; Ryan R Ahern; Kristen J Seog; Raffi Karagozian Journal: J Clin Exp Hepatol Date: 2021-02-04